# Articles

# Pre-existing sleep disturbances and risk of COVID-19: a meta-analysis

Jiawei Zhou, Xia Li, Ting Zhang, Ziyan Liu, Peng Li, Na Yu,\* and Wei Wang\*

Department of Respiratory and Critical Care Medicine, The First Hospital of China Medical University, Shenyang, China

#### Summary

**Background** Sleep disturbances are widespread but usually overlooked health risk factors for coronavirus disease 2019 (COVID-19). We aimed to investigate the influence of pre-existing sleep disturbances on the susceptibility, severity, and long-term effects of COVID-19.

Methods We searched PubMed, Web of Science, and Embase for relevant articles from inception to October 27, 2023 and updated at May 8, 2024. Sleep disturbances included obstructive sleep apnea (OSA), insomnia, abnormal sleep duration, night-shift work, and any other sleep disturbances. Outcomes were COVID-19 susceptibility, hospitalization, mortality, and long COVID. The effect sizes were pooled odds ratios (ORs) and 95% confidence intervals (95% CIs). This study is registered with PROSPERO (CRD42024503518).

Findings A total of 48 observational studies (n = 8,664,026) were included. Pre-existing sleep disturbances increased the risk of COVID-19 susceptibility (OR = 1.12, 95% CI 1.07-1.18), hospitalization (OR = 1.25, 95% CI 1.15-1.36), mortality (OR = 1.45, 95% CI 1.19-1.78), and long COVID (OR = 1.36, 95% CI 1.17-1.57). Subgroup analysis showed that younger individuals with sleep disturbances were associated with higher susceptibility and hospitalization and a lower risk of mortality than older individuals. Males with sleep disturbances were associated with higher mortality. For specific sleep disturbances, the susceptibility and hospitalization of COVID-19 were associated with OSA, abnormal sleep duration, and night-shift work; mortality of COVID-19 was linked to OSA; risk of long COVID was related to OSA, abnormal sleep duration and insomnia.

Interpretation Pre-existing sleep disturbances, especially OSA, increased the risk of COVID-19 susceptibility, hospitalization, mortality, and long COVID. Age and sex played important roles in the effect of sleep disturbances on COVID-19.

Funding The National Natural Science Foundation of China and the Key Laboratory of Respiratory Diseases of Liaoning Province.

**Copyright** © 2024 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Keywords: Pre-existing sleep disturbances; COVID-19; Long COVID; OSA

### Introduction

The coronavirus disease 2019 (COVID-19) pandemic has threatened global healthcare systems and brought about substantial morbidity and mortality for years. Although we are in the post-pandemic period, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) still persists, and the long-term sequelae of acute infection, known as long COVID, also need to be considered. At least 65 million individuals might have developed long COVID worldwide.<sup>1</sup> Long COVID is associated with a wide spectrum of symptoms, sometimes accompanying new-onset diseases.<sup>1</sup> It implied that substantial disease and economic burden caused by COVID-19 will be imposed on individuals and society in the foreseeable future.

Sleep disturbances, including insomnia, obstructive sleep apnea (OSA), poor sleep quality, and abnormal sleep duration, are ubiquitous yet widely neglected health risk factors for COVID-19. The global prevalence of sleep disturbances during the COVID-19 pandemic was 40.49%.<sup>2</sup> Jahrami et al.<sup>2</sup> further classified the population into six groups (patients with COVID-19, children and adolescents, healthcare workers, special populations with healthcare needs, university students,





#### eClinicalMedicine 2024;74: 102719 Published Online xxx https://doi.org/10. 1016/j.eclinm.2024. 102719

<sup>\*</sup>Corresponding author. 155 Nanjing North Street, Heping District, Shenyang, Liaoning Province, 110000, China.

<sup>\*\*</sup>Corresponding author. 155 Nanjing North Street, Heping District, Shenyang, Liaoning Province, 110000, China.

E-mail addresses: yunacmu@163.com (N. Yu), wwbycmu@126.com (W. Wang).

#### **Research in context**

#### Evidence before this study

Sleep disturbances, including insomnia, obstructive sleep apnea (OSA), poor sleep quality, and abnormal sleep duration, are ubiquitous yet widely neglected health risk factors for coronavirus disease 2019 (COVID-19). Several studies have investigated the impact of the COVID-19 pandemic on sleep disturbances. Inversely, little literature summarized whether and to what extent pre-existing sleep disturbances influenced COVID-19, especially long COVID. Till now, only two metaanalyses have reported that OSA increased the severity and mortality of COVID-19. These meta-analyses only focused on one specific type of sleep disturbances and neglected other important sleep disturbances, such as insomnia. Furthermore, it was still debatable whether patients with COVID-19 and pre-existing sleep disturbances were more vulnerable to developing long COVID. We searched PubMed, Web of Science, and Embase for relevant articles from inception to October 27, 2023 and updated at May 8, 2024, using the search terms ("sleep" OR "sleep disorders" OR "sleep duration" OR "sleep quality" OR "OSA") AND ("COVID-19" OR "SARS-CoV-2" OR "long COVID"). Observational studies reporting the association between pre-existing sleep disturbances and COVID-19 susceptibility, hospitalization, mortality, and long COVID were included.

#### Added value of this study

A total of 48 observational studies (n = 8,664,026) were included. Compared with previous studies that only focused on OSA, our study enrolled different kinds of sleep disturbances and systematically demonstrated the relationship between pre-existing sleep disturbances and COVID-19, especially long COVID. Pre-existing sleep disturbances increased the risk of COVID-19 susceptibility, hospitalization, mortality, and long COVID. Subgroup analysis showed that younger individuals with sleep disturbances were associated with higher susceptibility and hospitalization and a lower risk of mortality than older individuals. Males with sleep disturbances were associated with higher mortality. This study further investigated specific types of sleep disturbances and found that various sleep disturbances had different influences. OSA played a vital role not only in the whole clinical course of COVID-19 but also in the long COVID. Abnormal sleep duration elevated the risk of COVID-19 susceptibility, hospitalization, and long COVID. Insomnia escalated the risk of long COVID. Night-shift work increased the risk of COVID-19 susceptibility and hospitalization.

#### Implications of all the available evidence

By including all types of sleep disturbances, our meta-analysis comprehensively illustrated the influence of pre-existing sleep disturbances on the entire clinical course of COVID-19. It emphasized that sleep disturbances, especially OSA, significantly increased the risk of COVID-19 susceptibility, hospitalization, mortality and long COVID. These influences could be affected by age and gender. These findings urge the general population and healthcare workers to conduct early evaluation and intervention for individuals with sleep disturbances to mitigate the short- and long-term effects of COVID-19.

and the general population) and found that patients with COVID-19 had the highest prevalence, up to 52.39%. Sleep disturbances not only cause daytime drowsiness, work burnout, and low spirits but also induce immune deficiency and systematic inflammation.<sup>3</sup>

Several studies have investigated the impact of the COVID-19 pandemic on sleep disturbances.<sup>2</sup> Inversely, little literature summarized whether and to what extent pre-existing sleep disturbances influenced COVID-19, especially long COVID. Till now, only two metaanalyses have reported that OSA increased the severity and mortality of COVID-19.4,5 These meta-analyses only focused on one specific type of sleep disturbances and neglected other important sleep disturbances, such as insomnia. Furthermore, it was still debatable whether patients with COVID-19 and pre-existing sleep disturbances were more vulnerable to developing long COVID. For example, in a comprehensive analysis of three large cohorts (two adult cohorts and one pediatric cohort), L Mandel et al.6 suggested a positive association between OSA and long COVID; however, this association was attenuated in two adult cohorts and disappeared in the pediatric cohort after adjusting confounders. An international cross-sectional study, ICOSS-II, showed that insomnia was associated with an increased risk of long COVID,<sup>7</sup> whereas no significant association was detected in another study.<sup>8</sup>

Therefore, our meta-analysis aimed to (1) investigate the association between pre-existing sleep disturbances and COVID-19, including susceptibility, hospitalization, mortality, and long COVID-19; (2) calculate the effects of specific sleep disturbances on four outcomes and explore the potential associated factors.

#### Methods

# Search strategy and selection criteria

We searched PubMed, Web of Science, and Embase for relevant articles from inception to October 27, 2023, and an updated search was done on May 8, 2024, using the search terms ("sleep" OR "sleep disorders" OR "sleep duration" OR "sleep quality" OR "OSA") AND ("COVID-19" OR "SARS-CoV-2" OR "long COVID") (Supplementary Appendix 1). Additionally, an extra manual search was conducted by screening the references of relevant articles and reviews to identify additional studies that met the selection criteria. The exposure variables were pre-existing sleep disturbances, including OSA, insomnia, abnormal sleep duration (defined as sleep duration of less than 6 h or more than 9 h), night-shift work, evening chronotype, poor sleep quality, restless legs syndrome and so on, and recorded by electronic health records (polysomnography or International Classification of Diseases-10), interview, or self-report. Observational studies reporting the association between pre-existing sleep disturbances and COVID-19 susceptibility, hospitalization, mortality, or long COVID were included. Articles were excluded if they were: (1) unreported outcomes of interest, (2) case reports, letters, brief communications, or reviews, and (3) preprint studies. If the same cohort or data was reported in more than one study, we included only the one with the most comprehensive and recent information to avoid data duplication. Two investigators independently assessed the eligibility of the retrieved articles for inclusion, and any discrepancies were resolved by negotiation with a third investigator.

### Procedures

Two experienced researchers conducted the data extraction and quality assessment under the supervision of a third investigator. We extracted the following: (1) basic information: author, year of publication, region, study design, sample size, age, and male ratio; (2) exposures: type of sleep disturbances and corresponding measurements; and (3) outcomes: COVID-19 susceptibility, hospitalization, mortality, or long COVID and corresponding measurements. If odds ratio (OR) was unavailable, hazard ratio, relative risk ratio, or raw data were extracted to calculate the corresponding ORs. We used the Agency for Healthcare Research and Quality to assess the quality of the cross-sectional studies and the Newcastle-Ottawa Scale (NOS) to assess the quality of the cohort and case-control studies (Table S1). Ethical approval and informed consent were not applicable for this study.

## Statistical analysis

All analyses were performed with Stata 16.0 software. The effect sizes were pooled ORs and corresponding 95% confidence intervals (95% CIs) and the adjusted one was superior to the unadjusted one. High heterogeneity was defined as  $I^2 \ge 50\%$ . If  $I^2 \ge 50\%$ , a random-effects model was selected for pooled estimates, otherwise a fixed-effects model was adopted. Subgroup analysis, including age (<60 years old vs.  $\ge 60$  years old), income level (high vs. low and middle),<sup>9</sup> male proportion (<50% vs.  $\ge 50\%$ ), exposure measurement (self-report vs. interview vs. electronic health records), outcome measurement (self-report vs. electronic health records), study design (cohort vs. case–control vs. cross-sectional), adjusted for OR (yes vs. no), literature quality (cohort: NOS <7 vs. NOS  $\ge 7$ ), and long COVID

definition ( $\geq$ 1-month vs.  $\geq$ 3-month) were performed to explore the source of heterogeneity. Heterogeneity in the subgroups was evaluated by the  $I^2$  statistic (%). Between-subgroup heterogeneity was assessed by a P value. We calculated pooled estimates only if there were at least four studies in a category in order to reduce the potential bias caused by the low number of studies. The leave-one-out sensitivity analysis was used to evaluate the robustness of the pooled estimates. We performed additional sensitivity analyses to determine the influence of specific populations on the robustness of the pooled estimates by excluding (1) studies executed in women, (2) studies conducted in children, (3) studies performed in patients with diabetes, (4) studies with health worker proportion >50%, (5) studies with all the bias mentioned above. Egger's test was used to evaluate the symmetry of the funnel plot. If the funnel plot was asymmetrical, we conducted the trim-and-fill method to identify whether the source of asymmetry was from publication bias or not.10 Statistical significance was set at P < 0.05. This study is registered with PROSPERO (CRD42024503518).

#### Role of the funding source

The funding source had no role in the design, execution, analyses, interpretation of the data, or decision to submit results.

#### Results

A total of 9835 records were retrieved, 95 full-text articles were evaluated, and 48 studies with 8,664,026 participants met the inclusion and exclusion criteria (Fig. 1). We included 22 studies (5,416,808 participants) for susceptibility, 12 studies (5,110,351 participants) for hospitalization, 16 studies (5,573,387 participants) for mortality, and 11 studies (2,367,827 participants) for long COVID. The sample size ranged from 118 to 4,912,229, and the proportion of males ranged from 0% to 72%. The regions were spread over USA (n = 19), multinational (n = 5), UK (n = 5), China (n = 2), India (n = 2), Netherlands (n = 2), Switzerland (n = 2), Norway (n = 2), Finland (n = 2), Canada (n = 1), France (n = 1), Germany (n = 1), Japan (n = 1), Poland (n = 1), South Korea (n = 1), and Turkey (n = 1). These studies mainly included four types of sleep disturbances (OSA, insomnia, abnormal sleep duration, night-shift work) (Table 1).

#### Susceptibility

Individuals with pre-existing sleep disturbances were more susceptible to COVID-19 (OR = 1.12, 95% CI 1.07-1.18) (Table 2). For specific sleep disturbances, OSA, abnormal sleep duration, and night-shift work increased the occurrence of COVID-19 (Table 2). Subgroup analysis showed that the increased susceptibility of COVID-19 was more significant in the population Articles




Fig. 1: Flow chart of study.

from low- and middle-income countries (high-income: 1.11, 95% CI 1.05–1.16 vs. low- and middle-income: 3.63, 95% CI 2.58–5.78; P < 0.001) and in studies with unadjusted ORs (adjusted: 1.12, 95% CI 1.06–1.17 vs. unadjusted: 1.78, 95% CI 1.17–2.70; P = 0.030). In addition, younger individuals with pre-existing sleep disturbances were associated with an increased susceptibility to COVID-19 (OR = 1.20, 95% CI 1.11–1.30), while older individuals were not (Fig. 2).

#### Clinical courses of COVID-19

The odds of COVID-19 hospitalization were significantly higher in patients with pre-existing sleep disturbances (OR = 1.25, 95% CI 1.15–1.36) (Table 2). Except for insomnia, the other three types of sleep disturbances were associated with an increased probability of hospitalization. The association between pre-existing sleep disturbances and COVID-19 hospitalization was stronger in younger patients (age <60 years: 1.43, 95% CI 1.26–1.61 vs.  $\geq$ 60 years: 1.10, 95% CI 1.05–1.15; P < 0.001) (Fig. 2).

Pre-existing sleep disturbances increased the mortality of COVID-19 (OR = 1.45, 95% CI 1.19–1.78), mainly attributable to OSA (Table 2). The increased mortality of COVID-19 was more significant in the older patients (age <60 years: 1.22, 95% CI 0.91–1.62 vs.  $\geq$ 60 years: 2.07, 95% CI 1.59–2.68; P = 0.007) and in males (male ratio <50%: 1.09, 95% CI 0.94–1.27 vs.  $\geq$ 50%: 1.79, 95% CI 1.31–2.45; P = 0.005) (Fig. 2). Sensitivity analysis showed that after removing the study performed in patients with diabetes, the heterogeneity turned into low, which meant the population was the source of heterogeneity. Therefore, we extra performed a subgroup analysis and found that the association between pre-existing sleep disturbances and COVID-19 mortality was stronger in patients with diabetes than in the general population (diabetes: 2.80, 95% CI 1.46–5.38 vs. general population: 1.16, 95% CI 1.05–1.28; P = 0.009) (Figure S5).

#### Long COVID

Pre-existing sleep disturbances promoted the occurrence of long COVID (OR = 1.36, 95% CI 1.17-1.57) (Table 2). Subgroup analysis reported that the association between pre-existing sleep disturbances and long COVID was more significant in those whose definition of long COVID was symptoms  $\geq$ 3-month (3-month: 1.53, 1.24–1.91 vs. 1-month: 1.18, 1.09–1.29; P = 0.029) (Fig. 2). Abnormal sleep duration and insomnia increased the odds of long COVID. L Mandel et al. reported a strong association between OSA and long COVID (OR = 1.75, 95% CI 1.71-1.80). However, this association disappeared in the pooled estimates. High heterogeneity was caused by different definitions of long COVID between the study by L Mandel et al. and the other three studies. Therefore, we divided the studies into two groups based on the definition of COVID-19 and found that OSA increased the risk of long COVID

Bandma ch 2022Kowscossection89399 <sup>ment</sup> 90 <sup>ment</sup> 90.mspecifiedspecified00Bohma ch 2,022KAcossection10050 <sup>ment</sup> 6005A0Chou ch 2,023Multinicocossection191.0044 <sup>ment</sup> 48.0005A0Disterified (a 1,023)Multinicocossection191.0044 <sup>ment</sup> 48.0005A00Disterified (a 1,023)Misacolor725 <sup>ment</sup> 31.0005A00Goldscin (a 1,021)USAcolor725 <sup>ment</sup> 72005A00Hallan (a 1,2024USAcolor104.00104.00104.000 <t< th=""><th>Study</th><th>Region</th><th>Study design</th><th>Sample size</th><th>Age (years)</th><th>Males (%)</th><th>Type of sleep disturbances</th><th>Outcom</th></t<>	Study	Region	Study design	Sample size	Age (years)	Males (%)	Type of sleep disturbances	Outcom
ginart al 2003Matimationconse-section74.049 <sup>mm</sup> 95Night-diff work00Bjoratn et al, 2024Nawconse-section102955 <sup>mm</sup> 6605400000Borman et al, 2022USAconse-section102955 <sup>mm</sup> 6605400000Chon et al, 2023Matinationalconse-section19310041 <sup>mm</sup> 810005400000Chon et al, 2021USAconsert19310041 <sup>mm</sup> 810005400000Chon et al, 2021USAcohort5210051 <sup>mm</sup> 610005400000Cadden et al, 2021USAcohort812041 <sup>mm</sup> 470005400000Cadden et al, 2021USAcohort1845514 <sup>mm</sup> 470005400000Catable et al, 2021USAcohort1845514 <sup>mm</sup> 470005400000Catable et al, 2021USAcohort1845514 <sup>mm</sup> 470005400000Catable et al, 2021USAcohort193100014 <sup>mm</sup> 41000640000Catable et al, 2021USAcohort13100014 <sup>mm</sup> 4100004000000Catable et al, 2021USAcohort1329000014 <sup>mm</sup> 51000000Catable et al, 2021USAcohort1239000014 <sup>mm</sup> 15100000000000000000000000000000000000	Ahmadi et al., 2021	UK	cohort	468,569	57 <sup>mean</sup>	45	Poor sleep quality	3
Bindmart al, 2024.NonwayBindmart al, 2024.NonwayBindmart al, 2024.Sector al, 2020.Sector al, 2020. </td <td>Bjorvatn et al., 2023</td> <td>Norway</td> <td>cross-sectional</td> <td>988</td> <td></td> <td>40</td> <td></td> <td>1</td>	Bjorvatn et al., 2023	Norway	cross-sectional	988		40		1
And and et al., 2022         Use assorted         Log assorted         Set was assorted         Control         Control <thcontrol< th=""> <thcontro< th=""></thcontro<></thcontrol<>	Bjorvatn et al., 2023	Multinational	cross-sectional	7141	44 <sup>mean</sup>	35	Night-shift work	124
andou et al., 2020Francecohort33770""6505A05A0hund et al., 2023Multinationalcoss-sectional189144""A48mormaia0burstenfield et al., 2023USAcohort189144""A48mormaia0burstenfield et al., 2021USAcohort184053""3105A00biddide et al., 2021USAcohort816, 341""4705A00biddide et al., 2021USAcohort152, 259""30Ahonomal deep duration0cohort12, 2759""30Ahonomal deep duration0cohort13, 2759""3605A00cohort14, 2021UKcohort13, 2759""3600concol et al., 2021UKcohort13, 2759""68000concol et al., 2021USAcohort12, 29, 340""70000find et al., 2021USAcohort128, 344""18""70000i at al., 2021UKcohort128, 244""18""70000i at al., 2021UKcohort128, 344""18""18"18""000i at al., 2021UKcohort128, 344""18""18""0000i at al., 2021UK	3jorvatn et al., 2024	Norway	cross-sectional	893	49 <sup>mean</sup>	40		1
Inst et al. 2023         Multinational         coss-sectional         2891         44""         48         normia         0           chung et al. 2023         Multinational         coss-sectional         25.98         42""         35         05.A         0°           callable et al. 2021         USA         cohert         57         63"""         56         0.8	Bushman et al., 2022	USA	case-control	1029	56 <sup>median</sup>	66	OSA	3
Chang et al, 2073,Multinationconsertedial92,98(a)94,700095,60005A, incornal, ettale lage optione0Galdstain et al, 2021USAcohort87,73041,7044705A, incornal, ettale lage optione7Stability et al, 2021USAcohort86,73041,7044705A, incornal, ettale lage optione0Galdstain et al, 2021USAcohort18,45297,0000000Gonora et al, 2022USAcohort18,45297,00016000conser et al, 2023USAcohort32,336,61,70044,00150,00000conser et al, 2023Indiancohort32,336,47,07074,7000000conser et al, 2023Indiancohort32,336,47,07074,70000000conser et al, 2023Multinationcohort12,5287,80070000conser et al, 2023Multinationcohort12,5587,80070000conser et al, 2024Multinationcohort12,5587,8007000 <t< td=""><td>Cariou et al., 2020</td><td>France</td><td>cohort</td><td>1317</td><td></td><td>65</td><td>OSA</td><td>3</td></t<>	Cariou et al., 2020	France	cohort	1317		65	OSA	3
Chang et al, 2073,Multinationconsertedial92,98(a)94,700095,60005A, incornal, ettale lage optione0Galdstain et al, 2021USAcohort87,73041,7044705A, incornal, ettale lage optione7Stability et al, 2021USAcohort86,73041,7044705A, incornal, ettale lage optione0Galdstain et al, 2021USAcohort18,45297,0000000Gonora et al, 2022USAcohort18,45297,00016000conser et al, 2023USAcohort32,336,61,70044,00150,00000conser et al, 2023Indiancohort32,336,47,07074,7000000conser et al, 2023Indiancohort32,336,47,07074,70000000conser et al, 2023Multinationcohort12,5287,80070000conser et al, 2023Multinationcohort12,5587,80070000conser et al, 2024Multinationcohort12,5587,8007000 <t< td=""><td>Chen et al., 2023</td><td>Multinational</td><td>cross-sectional</td><td>1891</td><td>44<sup>mean</sup></td><td>48</td><td>Insomnia</td><td>4</td></t<>	Chen et al., 2023	Multinational	cross-sectional	1891	44 <sup>mean</sup>	48	Insomnia	4
Saddschin et al., 2021USAochort872 $3^{9^{malors}}$ 56S5, insomnia, restless legs gyndrome.90Sadtleb et al., 2021USAochort82141 <sup>malors</sup> 47OSA0Fisikan et al., 2021USAochort18,45MA47Abnormal slep duration0Ide tet al., 2022UKcohort18,45MA47Abnormal slep duration0onson et al., 2023UKcohort19,22759 <sup>malors</sup> 30Abnormal slep duration0orar et al., 2021UKAcohort232,396,160 <sup>malors</sup> 44.0insomnia, restless legs optical slep duration0Gar et al., 2021Indiacohort232,396,160 <sup>malors</sup> 630.00Gin et al., 2023Canadacohort238,490 <sup>Malors</sup> 333,64,2 <sup>47,00<sup>Malors</sup></sup> 53OSA00Gin et al., 2023UKcohort125,576S <sup>malors</sup> 50OSA00Li et al., 2021UKcohort162,61,7 <sup>malors</sup> 5131Malors00Adalsten et al., 2021UKcohort162,01Malors19000Li et al., 2021UKcohort125,01S <sup>malors</sup> 51000Li et al., 2021UKcohort173,01Malors190000Li et al., 2021UKcohort173,01Malors1900000<	Chung et al., 2023	Multinational	cross-sectional	20,598		35	OSA	12
bit         spratome	Durstenfeld et al., 2023	USA	cohort	1480			OSA	4
bialabar et al, 2021USAcolorS1294 <sup>man</sup> 9705A06A0légizian et al, 2024UKcois- et al52.77S <sup>man</sup> 300monal sleg duration0canno et al, 2020UKcolor13.11NA300.00monal sleg duration0canno et al, 2021Iniandcolor23.293.0560 <sup>man</sup> 4.40Isomial sleg duration0car et al, 2021Iniandcolor21.30S <sup>man</sup> 305A0.000in et al, 2023Canocolor21.30S <sup>man</sup> 3Sleg distubance0in et al, 2021Iniandcolor128.4S <sup>man</sup> 3Sleg distubance0in et al, 2021colorcolor125.5S <sup>man</sup> 3Sleg distubance0in et al, 2022colorcolor125.5S <sup>man</sup> 3Nonmal sleg duration, insom hyper0is et al, 2022colorcolor126.7S <sup>man</sup> 3Nonmal sleg duration, insom hyper0cal cla 2022kic et al, 2024Noncolor120.7Na3Nonmal sleg duration, insom hyper0cal cla 2021kic et al, 2024Noncolor120.7Na3Nonmal sleg duration, insom hyper0cal cla 2022Kic et al, 2024Na3Nonmal sleg duration, insom hyper0Nonmal sleg duration, insom hyper0cal cla 2022Kic et al, 2024NaSim3Nonmal sleg durati	Goldstein et al., 2021	USA	cohort	572	63 <sup>median</sup>	56		3
Hejazian et al., 2024USAcross-sectional108,455NA47Abnormal skep duration(9)Holf et al., 2022UKcohort15,22757%***30Abnormal skep duration(*)ones et al., 2023Finaldcohort392,396,67****4.4Irsonnia(*)(*)cer et al., 2021Indiacohort4,912,22947*****68OSA(*)(*)cer et al., 2021Multinationalcase-cortel28447*****7Sleep disturbance(*)(*)Andel et al., 2023USAcohort173,344****NA38***********(*)	Gottlieb et al., 2020	USA	cohort	8673	41 <sup>median</sup>	47	OSA	2
Hejazian et al., 2024UKcross-sectional108, 455NA47Abnormal sleep duration©iolit et al., 2022UKcohort15,22757 <sup>man</sup> 30Abnormal sleep duration©conse et al., 2023Finandcohort392,395,060 <sup>man</sup> 4,40Insomnia©car et al., 2021Indiacohort21357 <sup>matin</sup> 68OSA©Car et al., 2021Indiacohort21357 <sup>matin</sup> 53OSA©Car ada, 2023Winationalcas-control28447 <sup>matin</sup> 53OSA©Car ada, 2021Mutationalcas-control28447 <sup>matin</sup> 53OSA©Li et al., 2021cohort172,733,340 <sup>matin</sup> SSSSSOSA©Li et al., 2021cohort125,75SSS	Halalau et al., 2021	USA	cohort		49 <sup>mean</sup>	47	OSA	
Holt et al., 2022KKK </td <td>Hejazian et al., 2024</td> <td>USA</td> <td>cross-sectional</td> <td>108,455</td> <td>NA</td> <td></td> <td>Abnormal sleep duration</td> <td>4</td>	Hejazian et al., 2024	USA	cross-sectional	108,455	NA		Abnormal sleep duration	4
boannow et al., 2020USAcohort10,131NA36OSA $\bigcirc$ conse et al., 2023Finladcohort392,396, $\bigcirc$ $\bigcirc$ 4,4insomnia $\bigcirc$ Kendzenka et al., 2021Indiacohort213 $$$ $$$ $\bigcirc$							•	
ones et al., 2023Finlandcohort392,396,60 <sup>mum</sup> 44,Insomnia0Gar et al., 2021Indiacohort4,312, 2947 <sup>mak</sup> 5305A0Gendreska et al., 2023Ganadacohort4,912, 2947 <sup>mak</sup> 5305A0L. Mandel et al., 2023USAcohort1,78,34,947,0000000000000000000000000000000000								23
Car et al, 2021Indiacohort213 $55^{makan}$ 68OSA $\odot$ Car et al, 2023Canadacohort $4,212.229$ $47^{makan}$ 53OSA $\odot$ in et al, 2021Wish and a case-control2884 $48^{max}$ 72Sleep disturbance $\odot$ . Mandel et al, 2023USAcohort1783,940 <sup>WG</sup> , 33,642 <sup>VG, 100, 100,522<sup>VETSouth</sup>NA<math>38^{Max}</math><math>72</math>Sleep disturbance<math>\odot</math>. Mandel et al, 2021cohortcohort1125S8<sup>max</sup><math>50</math>OSA<math>\odot</math>. ju et al, 2022UKcohort125,575<math>68^{max}</math><math>32</math>Nahoromal sleep duration, incomos, and evening dronotype<math>\odot</math>. odia et al, 2021UKcohort120,07NANANight-shift work<math>\odot</math>. dakadari et al, 2021UKcohort123,040NANANight-shift work<math>\odot</math>. dakadari et al, 2021UKcohort123,040NANANa<math>\odot</math>. dakadari et al, 2021UKcohort123,040NANANA<math>\odot</math>. dakadari et al, 2022Japancross-sectional8837<math>43^{max}</math>49OSA<math>\odot</math>. dakadari et al, 2022UKcohort132,042NA49OSA<math>\odot</math>. dakadari et al, 2022UKcohort132,04NA49OSA<math>\odot</math>. dakadari et al, 2022USAcohort132,64<math>37^{max}</math>49OSA<math>\odot</math>. dakadari et al, 2022</sup>	,							
cenderska et al, 2023Canadacohort4,912,22947" windin53OSA0Mandel zl, 2021USAcohort1783,940%, 333,642°C00refS1*****S1************************************					55 <sup>median</sup>			
Cim et al., 2021Multinationalcasecontrol288448"****72Sleep disturbance0Mandel et al., 2023USAcohort1,733,540" <sup>VCCCMMM,</sup> 1335,642" <sup>VCCMMM,</sup> 165,622" <sup>VEDMM,</sup> SS					47 <sup>median</sup>			023
Mandel et al., 2023USAcohort $1,78,3940^{VVC}, 33,642^{VCDWH}, 35,642^{VCDWH}, 51^{VTDWH}}NA38^{VMG}, 40^{VCDWH}, 51^{VTDWH}}OSA©i et al., 2021cohortohort112558MHAA50OSA©iu et al., 2022UKcohort65,57668MHAA47Abnormal sleep duration, insomal, excessive daytime sleepines, and excessive daytime $								
Liu et al., 2022UK wither landscohort55,57668"" and scressive daytime sleep insomnia, excessive daytime sleep insomnia,<				1,783,940 <sup>N3C</sup> , 333,642 <sup>PCORnet</sup>	NA	38 <sup>N3C</sup> 40 PCORnet		
code et al., 2022       Netherlands       cohort       26,051       51 <sup>mean</sup> 38       Night-shift work       0         ohia et al., 2021       USA       cohort       1871       64 <sup>mean</sup> 52       0SA       0         Adadstone et al., 2021       UK       cohort       120,307       NA       NA       Night-shift work       0         Adashaqi et al., 2021       USA       cohort       1738       S <sup>Bmedan</sup> 49       0SA       0         Adashaqi et al., 2022       Japan       cross-sectional       837       43 <sup>medan</sup> 49       0SA       0         Valaidolinos et al., 2020       USA       cohort       122,040       NA       39       0SA       0         Valaidolinos et al., 2020       USA       cohort       1581       NA       49       Poor sleep quality       0         Valai et al., 2022       UK       cohort       1581       NA       49       Poor sleep quality       0         Valai et al., 2021       UK       cohort       1581       NA       49       OSA       0         Valai et al., 2021       UK       cohort       1587       71 <sup>medan</sup> 61       OSA       0       0         Valai	i et al., 2021	cohort	cohort	1125	58 <sup>mean</sup>	50	OSA	3
coef et al., 2022Netherlandscohort $26,051$ $51^{mean}$ $38$ Night-shift work $\odot$ $c_ohia et al., 2021$ USAcohort $1771$ $64^{mean}$ $52$ OSA $\odot$ Waldschore et al., 2021UKcohort $1738$ $58^{medan}$ $49$ OSA $\odot$ Waldschime et al., 2022Japancross-sectional $8837$ $37^{mean}$ $49$ OSA $\odot$ Shatshime et al., 2022Japancross-sectional $8837$ $37^{mean}$ $49$ OSA $\odot$ Shatshime et al., 2022USAcohort $122,040$ NA $39$ OSA $\odot$ $2^{halaidinos et al., 2020USAcohort20064^{mean}49Por sleep quality\odot2^{halaidinos et al., 2022UKcohort32053^{mean}54OSA\odot2^{halaidinos et al., 2022VKcohort19670^{medan}61OSA\odot2^{halaidinos et al., 2022Polandcohort184751^{medan}34Insomnia\odot2^{halaidinos et al., 2022Polandcohort184751^{mealan}49OSA\odot2^{han et al., 2023USAcross-sectional15,05746^{mean}49Insomnia, poor sleep quality,\odot2^{han et al., 2023(1)USAcross-sectional19,92646^{mean}49Insomnia, sleep duration\odot2^{han et al., 2024USAcross-sectional1$	iu et al., 2022	UK	cohort	65,576	68 <sup>mean</sup>	47	excessive daytime sleepiness, and	10
Johia et al., 2021USAcohort187164 <sup>mana</sup> 52OASASWaidstone et al., 2021UKcohort120,307NANANaphershift workSWashagi et al., 2021USAcohort1738S <sup>median</sup> 49OSASNakashima et al., 2022Japancoss-sectional883743 <sup>meana</sup> 49OSASPalad et al., 2022UKcohort122,040NA39OSASSPalad et al., 2022UKcohort128,10A49Poor sleep qualitySSPalad et al., 2022UKcohort1361SSSSSSSPalad et al., 2020UKcohort19670 <sup>median</sup> 61OSASSPalad et al., 2020Switzerlancohort184751 <sup>median</sup> 34InsomniaSSPalad et al., 2021Sintercohort19670 <sup>median</sup> 61OSASSPalad et al., 2023VIAcohort184751 <sup>median</sup> 37Seep disordersSSPalad et al., 2023(1)USAcross-sectional19,92646 <sup>meana</sup> 49OSASSQuan et al., 2024USAcross-sectional19,92646 <sup>meana</sup> 49Seep disordersSSQuan et al., 2024Indiacross-sectional19,71044 <sup>meana</sup> 41Seep ophernsSSSichiling et al., 202	_oef et al., 2022	Netherlands	cohort	26,051	51 <sup>mean</sup>	38	• • • •	1
Maidstone et al., 2021UKcohort120,307NANANANight-shift work $\odot$ Mashaqi et al., 2021USAcohort173858 <sup>median</sup> 49OSA $\odot$ Vakashima et al., 2022Japancross-sectional83743 <sup>mean</sup> 49OSA $\odot$ Dh et al., 2021South Koreacohort122,040NA39OSA $\odot$ $\odot$ Palaidimos et al., 2020USAcohort20064 <sup>melan</sup> 49OSA $\odot$ $\odot$ Palaidimos et al., 2021UKcohort1581NA49Poor sleep quality $\odot$ $\odot$ $\odot$ Pale et al., 2021UKcohort120 $\Im$ $\Im$ $\Theta$ $\odot$ <td></td> <td>USA</td> <td></td> <td></td> <td>64<sup>mean</sup></td> <td></td> <td></td> <td></td>		USA			64 <sup>mean</sup>			
Mashaqi et al., 2021USAcohort173858 median49OSA9Nakashima et al., 2022Japancross-sectional883743 man49OSA0Palaiofinos et al., 2021South Koreacohort122,040NA39OSA00Palaiofinos et al., 2022UKcohort128,0064 median49OSA000Pala et al., 2022UKcohort1581NA49OSA000Pellad et al., 2020UKcohort1967061OSA000Pellad et al., 2021UKcohort1967061OSA000Pellad et al., 2022Polandcohort1967061OSA000Pellad et al., 2023USAcohort196,775134Insomnia0000Polan et al., 2023(1)USAcross-sectional15,057464905A00<								
Vakashima et al., 2022Japancross-sectional883743 mean49OSAOOh et al., 2021South Koreacohort122,040NA39OSAOOPalaiodimos et al., 2020USAcohort20064 medan49OSAOOPala et al., 2021UKcohort1581NA49Poor sleep qualityGPale et al., 2021UKcohort1581NA49Poor sleep qualityGPeker et al., 2020Switzerlandcohort19670 medan61OSAOPula et al., 2022Polandcohort184751 medan34InsomniaGPunj et al., 2023USAcohort49,43459 mean37Sleep disordersOOQuan et al., 2023(1)USAcross-sectional15,05746 mean49OSAOOQuan et al., 2024USAcross-sectional19,92646 mean49Insomnia poor sleep quality, abrormal sleep durationOOQuan et al., 2023Germanycross-sectional17,1044 mean41Sleep problemsGSishah et al., 2021Indiacross-sectional17,5038 mean0Abnormal sleep duration, night-shift workOSishah et al., 2023USAcross-sectional17,5039 mean37OSAOSishah et al., 2023USAcross-sectional75039 mean8Night-shift workO<								
De te al., 2021South Koreacohort122,040NA39OSA $\bigcirc$ Palaiodimos et al., 2020USAcohort200 $64^{median}$ 49OSA $\bigcirc$ Paul et al., 2021UKcohort1581NA49Poor sleep quality $\bigcirc$ Peleid et al., 2020Switzerlandcohort320 $53^{mean}$ 54OSA $\bigcirc$ Peleid et al., 2020Switzerlandcohort196 $70^{median}$ 61OSA $\bigcirc$ Poun et al., 2023VISAcohort1847 $51^{median}$ 34Insomnia $\bigcirc$ Quan et al., 2023(1)USAcohort49,434 $59^{mean}$ 37Sleep disorders $\bigcirc$ Quan et al., 2023(2)USAcross-sectional1,505746^{mean}49Insomnia, poor sleep quality, $\bigcirc$ $\bigcirc$ Quan et al., 2023(2)USAcross-sectional1,926 $46^{mean}$ 49Shormal sleep duration $\bigcirc$ Quan et al., 2024USAcross-sectional1,71044^{mean}41Sleep problems $\bigcirc$ Shah et al., 2023Germanycross-sectional1,71044^{mean}37OSA $\bigcirc$ Shah et al., 2024Indiacross-sectional1,70044^{mean}41Sleep problems $\bigcirc$ Shah et al., 2023USAcross-sectional1,50739^{mean}37OSA $\bigcirc$ Shah et al., 2023USAcohort44553^{mean}37OSA $\bigcirc$ Shah et al., 2023 <td></td> <td></td> <td></td> <td></td> <td>5.</td> <td></td> <td></td> <td></td>					5.			
Palaiodimos et al., 2020USAcohort20064 <sup>median</sup> 49OSA9Paul et al., 2021UKcohort1581NA49Poor sleep quality0Peker et al., 2021Turkeycohort32053 <sup>mean</sup> 54OSA0Pellaud et al., 2020Switzerlandcohort19670 <sup>median</sup> 61OSA0Polywaczewska-Jakubowska et al., 2022Polancohort184751 <sup>median</sup> 34Insomnia0Polan et al., 2023USAcohort49,43459 <sup>mean</sup> 37Sleep disorders00Quan et al., 2023(2)USAcohort15,05746 <sup>mean</sup> 49OSA00Quan et al., 2023(2)USAcross-sectional19,92646 <sup>mean</sup> 49Insomnia, poor sleep quality, abnormal sleep duration0Quan et al., 2024USAcross-sectional19,82146 <sup>mean</sup> 49Sleep foblems0Shah et al., 2021Indiacross-sectional17,1044 <sup>mean</sup> 41Sleep problems0Simans et al., 2023USAcohort44553 <sup>mean</sup> 37OSA00Simans et al., 2023USAcohort83967 <sup>median</sup> 40Sleep duration, night- shift work0Quan et al., 2023USAcohort83967 <sup>median</sup> 37OSA0Simans et al., 2023USAcohort83967 <sup>median</sup> 41OSA0Simans et al., 2		•						
Paul et al., 2022UKcohort1581NA49Poor sleep quality(a)Peker et al., 2021Turkeycohort32053 <sup>mean</sup> 54OSA(a)Pellaud et al., 2020Switzerlandcohort19670 <sup>median</sup> 61OSA(a)Phywaczewska-Jakubowska et al., 2022Polandcohort184751 <sup>median</sup> 34Insomnia(a)Punj et al., 2023USAcohort49,43459 <sup>mean</sup> 37Sleep disorders(a)Quan et al., 2023(1)USAcross-sectional19,05746 <sup>mean</sup> 49OSA(a)Quan et al., 2023(2)USAcross-sectional19,92646 <sup>mean</sup> 49Insomnia, poor sleep quality, abnormal sleep duration(a)Quan et al., 2024USAcross-sectional1,71044 <sup>mean</sup> 41Sleep problems(a)Schilling et al., 2023Germanycross-sectional1,71044 <sup>mean</sup> 37OSA(a)Schilling et al., 2023Indiacross-sectional1,71044 <sup>mean</sup> 41Sleep problems(a)Schilling et al., 2023Indiacross-sectional1,7103 <sup>mean</sup> 37OSA(a)(a)Schilling et al., 2023USAcohort4553 <sup>mean</sup> 37OSA(a)(a)Schilling et al., 2023USAcohort4553 <sup>mean</sup> 37OSA(a)(a)Schilling et al., 2023USAcohort4503 <sup>mean</sup> 37OSA								
Peker et al., 2021Turkeycohort3205354OSAØPellaud et al., 2020Switzerlandcohort1967061OSAØPhywaczewska-Jakubowska et al., 2022Polandcohort18475134InsomniaØPunj et al., 2023USAcohort49,4345937Sleep disordersØQuan et al., 2023(1)USAcross-sectional15,0574649Insomnia, poor sleep quality, abromal sleep durationØQuan et al., 2023(2)USAcross-sectional19,9264649Insomnia, poor sleep quality, abromal sleep durationØQuan et al., 2024USAcross-sectional19,8214649Isomnia sleep durationØSchilling et al., 2023Germanycross-sectional11,7104441Sleep problemsØSchilling et al., 2021Finlandcohort44553380Abnormal sleep duration, night-shift workØStrausz et al., 2021Kiacross-sectional7503937OSAØØSwanson et al., 2023USAcohort83967540SAØ36Might-shift workØGermanycross-sectional7503937OSAØØ36Might-shift workØØSwanson et al., 2023USAcohort8396770SAØØ36Might-shift workØGreman e								
Perellaud et al., 2020Switzerlandcohort1967061OSA9Phywaczewska-Jakubowska et al., 2022Polandcohort18475134Insomnia9Punj et al., 2023USAcohort49,4345937Sleep disorders99Quan et al., 2023(1)USAcross-sectional15,05746490SA99Quan et al., 2023(2)USAcross-sectional19,9264649Insomnia, poor sleep quality, abnormal sleep duration9Quan et al., 2024USAcross-sectional19,8214641Sleep problems9Schilling et al., 2023Germanycross-sectional11,7104441Sleep problems9Schilling et al., 2022Iniandcohort44553389Shah et al., 2023USAcross-sectional15,0573937OSA9Strasz et al., 2021Finlandcohort445533937OSA99Vargas et al., 2023USAcross-sectional750398Night-shift work9Vargas et al., 2023USAcohort83967540SA99Vargas et al., 2023USAcohort83967540SA99Vargas et al., 2023USAcohort83967540SA99Vargas et al., 2023USAcohort188469 <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>								
Adjwaczewska-jakubowska et al., 2022Polandcohort18475151addInsomnia0Punj et al., 2023USAcohort49,434595937Sleep disorders02Quan et al., 2023(1)USAcross-sectional15,0574649OSA02Quan et al., 2023(2)USAcross-sectional19,9264649Insomnia, poor sleep quality, abnormal sleep duration02Quan et al., 2024USAcross-sectional19,8214649Sleep roblems0Quan et al., 2023Germanycross-sectional11,7104441Sleep problems0Schilling et al., 2022Indiacross-sectional1503837OSA0Statusz et al., 2021Finlandcohort4455337OSA0Statusz et al., 2023USAcross-sectional7503937OSA0Statusz et al., 2023USAcohort839670SA03Statusz et al., 2023USAcohort839670SA03Statusz et al., 2023USAcohort839670SA33Statusz et al., 2023USAcohort839670SA33Statusz et al., 2023USAcohort839670SA33Statusz et al., 2023USAcohort83469570SA33Stat								
Punj et al., 2023USAcohort49,43459510Quan et al., 2023(1)USAcross-sectional15,0574649OSA0Quan et al., 2023(2)USAcross-sectional19,9264649Insomnia, poor sleep quality, abnormal sleep duration0Quan et al., 2024USAcross-sectional19,8214649Evening chronotype, night-shift0Quan et al., 2023Germanycross-sectional19,8214649Evening chronotype, night-shift0Quan et al., 2024USAcross-sectional11,7104441Sleep problems0Schilling et al., 2022Indiacross-sectional1503837OSA0Shah et al., 2021Finlandcohort4455337OSA0Swanson et al., 2023USAcross-sectional7503937OSA0Swanson et al., 2023USAcohort83967640SA3Yargas et al., 2023USAcohort83967640SA3Yargas et al., 2022Netherlandscohort18846967670SA3Yargas et al., 2022Netherlandscohort18846967670SA3Yargas et al., 2022Chinacohort18846967670SA3Yargas et al., 2020Chinacohort1884696767								
Quan et al., 2023(1)USAcross-sectional15,05746 <sup>mean</sup> 49OSA①Quan et al., 2023(2)USAcross-sectional19,92646 <sup>mean</sup> 49Insomnia, poor sleep quality, abnormal sleep duration①Quan et al., 2024USAcross-sectional19,82146 <sup>mean</sup> 49Evening chronotype, night-shift work①Quan et al., 2023Germanycross-sectional11,71044 <sup>mean</sup> 41Sleep problems④Schilling et al., 2023Germanycross-sectional15038 <sup>mean</sup> 0Abnormal sleep duration, night- shift work①Strausz et al., 2021Finlandcohort44553 <sup>mean</sup> 37OSA②Swanson et al., 2023USAcross-sectional75039 <sup>mean</sup> 8Night-shift work③Yargas et al., 2023USAcohort83967 <sup>median</sup> 54OSA③Yargas et al., 2022Netherlandscohort188469 <sup>mean</sup> 57OSA③Wang et al., 2020Chinacohort11831 <sup>mean</sup> 36Night-shift work④	•							
Quan et al., 2023(2)USAcross-sectional19,92646 <sup>mean</sup> 49Insomnia, poor sleep quality, abnormal sleep duration(2)Quan et al., 2024USAcross-sectional19,82146 <sup>mean</sup> 49Evening chronotype, night-shift work(3)Schilling et al., 2023Germanycross-sectional11,71044 <sup>mean</sup> 41Sleep problems(4)Schah et al., 2022Indiacross-sectional15038 <sup>mean</sup> 0Abnormal sleep duration, night- shift work(1)Strausz et al., 2021Finlandcohort44553 <sup>mean</sup> 37OSA(2)Swanson et al., 2023USAcross-sectional75039 <sup>mean</sup> 8Night-shift work(2)Vargas et al., 2021Switzerlandcohort83967 <sup>median</sup> 54OSA(3)Vargas et al., 2023USAcohort297447 <sup>mean</sup> 19Insomnia(3)Vargas et al., 2022Netherlandscohort188469 <sup>mean</sup> 57OSA(3)Wang et al., 2020Chinacohort11831 <sup>mean</sup> 36Night-shift work(3)					59			
Again et al., 2024USAcross-sectional19,82146 <sup>mean</sup> 49Evening chronotype, night-shift, work0Schilling et al., 2023Germanycross-sectional11,71044 <sup>mean</sup> 41Sleep problems0Shah et al., 2022Indiacross-sectional15038 <sup>mean</sup> 0Abnormal sleep duration, night- shift work0Strausz et al., 2021Finlandcohort44553 <sup>mean</sup> 37OSA0Swanson et al., 2023USAcross-sectional75039 <sup>mean</sup> 8Night-shift work0Tessitore et al., 2021Switzerlandcohort83967 <sup>median</sup> 54OSA0Vargas et al., 2023USAcohort297447 <sup>mean</sup> 19Insomnia0Voncken et al., 2022Netherlandscohort188469 <sup>mean</sup> 56Night-shift work0Wang et al., 2020Chinacohort11831 <sup>mean</sup> 36Night-shift work0								
Schuling et al., 2023Germanycross-sectional11,7104441Sleep problems@Shah et al., 2022Indiacross-sectional150380Abnormal sleep duration, night- shift work0Strausz et al., 2021Finlandcohort4455337OSA@Swanson et al., 2023USAcross-sectional7503998Night-shift work0Fessitore et al., 2021Switzerlandcohort8396764OSA3/argas et al., 2023USAcohort29744719Insomnia0/oncken et al., 2022Netherlandscohort18846957OSA0Wang et al., 2020Chinacohort1183136Night-shift work0							abnormal sleep duration	
Shah et al., 2022Indiacross-sectional15038 <sup>mean</sup> 0Abromal sleep duration, night- shift work0Strausz et al., 2021Finlandcohort44553 <sup>mean</sup> 37OSA2Swanson et al., 2023USAcross-sectional75039 <sup>mean</sup> 8Night-shift work0Tessitore et al., 2021Switzerlandcohort83967 <sup>median</sup> 54OSA3Vargas et al., 2023USAcohort297447 <sup>mean</sup> 19Insomnia0Voncken et al., 2022Netherlandscohort188469 <sup>mean</sup> 57OSA0Wang et al., 2020Chinacohort11831 <sup>mean</sup> 36Night-shift work0							work	
Strausz et al., 2021       Finland       cohort       445       53 <sup>mean</sup> 37       OSA       20         Swanson et al., 2023       USA       cross-sectional       750       39 <sup>mean</sup> 8       Night-shift work       0         Tessitore et al., 2021       Switzerland       cohort       839       67 <sup>median</sup> 54       OSA       39         Vargas et al., 2023       USA       cohort       2974       47 <sup>mean</sup> 19       Insomnia       0         Voncken et al., 2022       Netherlands       cohort       1884       69 <sup>mean</sup> 57       OSA       03         Wang et al., 2020       China       cohort       118       31 <sup>mean</sup> 36       Night-shift work       0	<b>3</b>							
Swanson et al., 2023USAcross-sectional7503939Night-shift work0Fessitore et al., 2021Switzerlandcohort8396754OSA3/argas et al., 2023USAcohort2974479Insomnia0/oncken et al., 2022Netherlandscohort18846957OSA03Wang et al., 2020Chinacohort1183136Night-shift work0	5hah et al., 2022	India	cross-sectional	150	-	0		1
Fessitore et al., 2021Switzerlandcohort839 $67^{median}$ 54OSAImage: SA/argas et al., 2023USAcohort2974 $47^{mean}$ 19InsomniaImage: SAImage: SAImage: Image: SAImage: Image: SAImage: Image: SAImage: SA<	Strausz et al., 2021	Finland	cohort	445		37	OSA	2
Vargas et al., 2023USAcohort297447 <sup>mean</sup> 19Insomnia0/oncken et al., 2022Netherlandscohort188469 <sup>mean</sup> 57OSA03Wang et al., 2020Chinacohort11831 <sup>mean</sup> 36Night-shift work0	Swanson et al., 2023	USA	cross-sectional	750	39 <sup>mean</sup>	8	Night-shift work	1
Vargas et al., 2023USAcohort297447 mean19Insomnia0/oncken et al., 2022Netherlandscohort1884 $69^{mean}$ 57OSA $33$ Wang et al., 2020Chinacohort118 $31^{mean}$ 36Night-shift work $0$	Fessitore et al., 2021	Switzerland	cohort	839	67 <sup>median</sup>	54	OSA	3
Voncken et al., 2022Netherlandscohort188469 <sup>mean</sup> 57OSA①Wang et al., 2020Chinacohort11831 <sup>mean</sup> 36Night-shift work①	Vargas et al., 2023	USA	cohort		47 <sup>mean</sup>	19	Insomnia	1
Wang et al., 2020 China cohort 118 31 <sup>mean</sup> 36 Night-shift work ①	•				69 <sup>mean</sup>			13
		China			31 <sup>mean</sup>		Night-shift work	
Wang et al., 2023(1) USA cohort 1981 65 <sup>meau</sup> 0 Abnormal sleep duration (4)	Wang et al., 2023(1)	USA	cohort	1981	65 <sup>mean</sup>	0	Abnormal sleep duration	4

Study	Region	Study design	Sample size	Age (years)	Males (%)	Type of sleep disturbances	Outcomes
(Continued from previous page)							
Wang et al., 2023(2)	USA	cohort	1979	65 <sup>mean</sup>	0	Evening chronotype, insomnia, daytime dysfunction	4
Xue et al., 2023	Multinational	cross-sectional	5918	45 <sup>mean</sup>	37	Abnormal sleep duration	4
Abbreviation: OSA, obstructive sleep apnea. ①susceptibility, ②hospitalization, ③ mortality, ④ long COVID.							
Table 1: Basic characteristics of included studies.							

in both groups (3-month: 1.75, 1.71–1.80 vs. 1-month: 1.12, 1.08–1.16; P < 0.001) (Figure S6). These results suggested that OSA was a risk factor for susceptibility to long COVID, but the results should be interpreted with caution.

#### Publication bias, quality control and sensitivity analysis

Asymmetric funnel plots had been observed in studies on COVID-19 susceptibility (P = 0.007), hospitalization (P = 0.033), and mortality (P = 0.008), indicating potential risks of publication bias (Figures S1.9, S2.9, and S3.9). In studies on COVID-19 susceptibility and hospitalization, the results from the trim-and-fill method indicated that the asymmetry in the funnel plot was more likely to be introduced by other reasons, such as poor study quality and selection bias (Figures S1.11 and S2.11), instead of publication bias (Table S2). In terms of COVID-19 mortality, there was a suggestion of publication bias (Table S2), which might lead to the asymmetry in the funnel plot. No evidence for publication bias was detected for long COVID (P = 0.364) (Figure S4.10). Three subgroups representing good quality (cohort study, adjusted ORs, and NOS  $\geq$  7) illustrated that the associations between pre-existing sleep disturbances and the four outcomes were consistent with the main analyses (Fig. 2). In addition, the results of leave-one-out sensitivity analyses

Sleep disturbances	Sample size	Number	OR (95% CI)	l <sup>2</sup> (%)
COVID-19 susceptibility				
Any sleep disturbances	6,297,547	40	1.12 (1.07-1.18)	84.6
OSA	5,079,484	6	1.64 (1.28-2.10)	90.7
Abnormal sleep duration	203,434	8	1.07 (1.02–1.13)	17.9
Insomnia	547,436	6	0.98 (0.96–1.00)	0
Night-shift work	195,052	9	1.49 (1.13-1.96)	74.7
Other sleep disturbances	272,141	11	1.09 (1.12–1.16)	77.5
COVID-19 hospitalization				
Any sleep disturbances	5,563,585	21	1.25 (1.15–1.36)	71.7
OSA	4,968,274	8	1.49 (1.23-1.80 )	57.2
Abnormal sleep duration	171,004	4	1.20 (1.09–1.33)	0
Insomnia	151,078	3	1.08 (1.00-1.17)	0
Night-shift work	7141	1	5.66 (1.89–16.95)	NA
Other sleep disturbances	266,088	5	1.17 (1.06–1.30)	56.3
COVID-19 mortality				
Any sleep disturbances	5,573,370	18	1.45 (1.19–1.78)	55.5
OSA	5,054,223	14	1.52 (1.20–1.94)	64.7
Insomnia	572	1	1.64 (0.75-3.57)	NA
Other sleep disturbances	518,575	3	1.16 (0.79-1.72)	0
Long COVID				
Any sleep disturbances	2,285,227	20	1.36 (1.17–1.57)	96.5
OSA	2,225,324	4	1.25 (0.90-1.74)	99.3
Abnormal sleep duration	128,215	7	1.25 (1.05-1.47)	66.5
Insomnia	5717	3	1.17 (1.06–1.30)	0
Night-shift work	7141	1	1.08 (0.43-2.70)	NA
Other sleep disturbances	18,830	5	1.92 (1.24-2.97)	94.9
Abbreviation: OSA, obstructive sleep apro	a. Bold means that the result was	statistically significant ( $P < 0.0$	r)	

COVID-19 susceptibility						
	Sample size	Number		OR (95%CI)	12(%)	Р
≺60y ≥60y Male ratio	5204535 852151	29 9	+	1·20(1·11-1·30) 1·01(0·99-1·03)	78 40·3	0.055
<50% ≥50% Income level	1261404 4915836	32 3		1-12(1-07-1-18) NA	82-5 NA	NA
Low and Middle Exposure measurement	6267842 568	33 4	· · · · · · · · · · · · · · · · · · ·	1·11(1·05-1·16) 3·63(2·58-5·78)	85·2 0	=0.001
	821761	32	rașe i	1.09(1.04-1.14)	79.4	0.097
Interview Electronic health records Outcome measurement	450 5476822 237844	3 5 22		NA 1-22(1-08-1-39)	NA 92-2 77-2	
Self-report Electronic health records Study design	6059703	22 18		1·15(1·05-1·27) 1·10(1·04-1·16)	88.2	0.372
Cohort Case-control Cross-sectional	6115758 2884 180391	18 1 21		1-09(1-03-1-14) NA 1-23(1-09-1-39)	86-3 NA	0.058
Adjusted for OR Yes No	5902372 396661	33 7		1·12(1·06-1·17) 1·78(1·17-2·70)	85.4	0.03
Literature quality	3092	2 16		NA 1.08(1.03-1.14)	NA 87-5	NA
NOS27	6112666	16		1.08(1.03-1.14)	87.5	
B COVID-19 hospitalization			0 1 2 3 4			
Age	Sample size	Number	1	OR (95%CI)	l <sup>2</sup> (%)	Р
<60y ≥60y	5094422 459032	13 7	· · · · · · · · · · · · · · · · · · ·	1·43(1·26-1·61) 1·10(1·05-1·15)	53·1 0	<0.001
Male ratio <50% ≥50%	651036 4912549	19 2	-	1·21(1·13-1·31) NA	58 NA	NA
Income level High Low and Middle	5535526 320	18 1		1·23(1·13-1·33) NA	71-2 NA	NA
Exposure measurement Self-report Electronic health records	581852 4981733	15 6	·	1·20(1·11-1·29) 1·36(1·11-1·72)	54·2 68·5	0.223
Outcome measurement Self-report Electronic health records	122500 5441085	7		1.41(1.19-1.67) 1.21(1.09-1.32)	51·1 75·2	0.105
Study design Cohort Cross-sectional	5441085 122500	14 7	·	1·21(1·09-1·32) 1·41(1·19-1·67)	75.2	0.105
Adjusted for OR Yes	5562764 821	20		1-23(1-14-1-34)	69-5 NA	NA
Literature quality	821	1		NA	NA	NA
NOS≥7	5440264	13		1.17(1.07-1.28)	72.5	
<b>^</b>			0 1 2 3 4			
COVID-19 mortality	Sample size	Number		OR (95%CI)	I <sup>2</sup> (%)	Р
Age <60y ≥60y	5434337 6862	7 9	+ • · · · · · · · · · · · · · · · · · ·	1.22(0.91-1.62) 2.07(1.59-5.68)	52·4	0.002
Male ratio <50%	652112	6		1.09(0.94-1.27)	1.8	0.005
≥50% Income level High	4921258 5573023	12 16		1·79(1·31-2·45) 1·38(1·13-1·68)	64·1 53·4	NA
Low and Middle Exposure measurement Self-report	1338	2		NA	NA	
Self-report Interview Electronic health records	468569 213 5104588	1 1 16		NA NA 1-46(1-18-1-81)	NA NA 56-9	NA
Outcome measurement Self-report	NA	NA		NA	NA	NA
Electronic health records Study design	5573370	18		1.45(1.19-1.78)	55.5	
Cohort Case-control Adjusted for OR	5572341 1029	17		1·46(1·18-1·80) NA	57-1 NA	NA
Yes No	5572974 396	16 2		1-44(1-17-1-78) NA	59-2 NA	NA
NOS=7 NOS=7	1317 5571024	1 16		NA 1·37(1·12-1·68)	NA 50-6	NA
D			0 1 2 3 4			
Long COVID	Sample size	Number		OR (95%CI)	1 <sup>2</sup> (%)	Р
Age <60y ≥60y	142167 13867	8	— • — · · · · · · · · · · · · · · · · ·	1-44(1-08-1-91) 1-16(1-08-1-24)	80.2	0.152
Male ratio <50%	2278965	19		1.38(1.19-1.60)	96.6	NA
≥50% Income level High	106262 2364359	1	<b>_</b>	NA 1-36(1-17-1-57)	NA 96.5	NA
Low and Middle Exposure measurement Self-report	NA 52928	NA 16		NA 1-41(1-19-1-65)	NA 85.7	NA
Self-report Interview Electronic health records Outcome measurement	108455 2223844	18 1 3		NA NA	NA NA	NA
Self-report Electronic health records	161383 2223844	17 3		1·37(1·17-1·60) NA	85.9 NA	NA
Study design Cohort Cross-sectional	2244194 141033	14 6		1·28(1·08-1·52) 1·55(1·09-2.19)	97·3 85·9	0.337
Adjusted for OR Yes No	2364359 NA	16 NA		1-36(1-17-1-57) NA	96.5 NA	NA
No Literature quality NOS≤7 NOS≥7	NA 17023 2227171	25		NA 1-26(1-10-1-45) 1-22(0-91-1-63)	67-5 99-1	0.83
≥1 month	458407	12		1.18(1.09-1.29)	60.6	0.029
≥3 months	1919679	7		1.53(1.24-1.91)	92.5	
			5 1 Z 3 4			

Fig. 2: Forest plot that demonstrates the association of pre-existing sleep disturbances with four types of outcomes. Abbreviation: NOS, Newcastle–Ottawa Scale.

(Figures S1.12, S2.12, S3.12, and S4.11) and those removing specific population sensitivity analyses (Table 3) were consistent with the main analyses, confirming the robustness of our results.

#### Discussion

Compared with previous studies that only focused on OSA, our study enrolled different kinds of sleep disturbances and systematically demonstrated the relationship between pre-existing sleep disturbances and COVID-19, especially long COVID. Our results indicated that pre-existing sleep disturbances increased the risk of COVID-19 susceptibility, hospitalization, mortality, and long COVID. Subgroup analysis showed that younger individuals with sleep disturbances were associated with a higher risk of COVID-19 susceptibility and hospitalization and a lower risk of mortality than older individuals. Males with sleep disturbances were associated with higher risks of COVID-19 mortality than females. We further investigated specific types of sleep disturbances and found that various sleep disturbances had different influences. OSA played a vital role not only in the whole clinical course of COVID-19 but also in the long COVID. Abnormal sleep duration elevated the risk of COVID-19 susceptibility, hospitalization, and long COVID. Insomnia escalated the risk of long COVID. Night-shift work increased the risk of COVID-19 susceptibility and hospitalization. These findings urge the general population and healthcare workers to conduct early evaluation and intervention for individuals with sleep disturbances to mitigate the short- and long-term effects of COVID-19.

Insomnia and sleep-related breathing disorders are the top two types of sleep disorders. Their common manifestation is insufficient sleep duration. We observed that pre-existing sleep disturbances increased the risk of COVID-19 susceptibility, hospitalization,

Components	Sample size	Number	OR (95% CI)	l <sup>2</sup> (%)
COVID-19 susceptibility				
Main analysis	6,297,547	40	1.12 (1.07-1.18)	84.6
Women studies removal	6,298,583	37	1.11 (1.06–1.16)	84.3
Health worker proportion >50% studies removal	6,268,780	33	1.11 (1.06–1.16)	85.2
All the biased studies removal	6,268,780	33	1.11 (1.06–1.16)	85.2
COVID-19 mortality				
Main analysis	5,573,370	18	1.45 (1.19–1.78)	55.5
Diabetes study removal	5,572,053	17	1.37 (1.33-1.66)	49.0
Long COVID				
Main analysis	2,285,227	20	1.38 (1.19–1.60)	96.6
Children studies removal	2,278,965	19	1.36 (1.18-1.57)	95.9
Women studies removal	2,371,366	13	1.40 (1.24–1.81)	97.6
All the biased studies removal	2,265,104	12	1.55 (1.27-1.90)	97.7

mortality, and long COVID. One study administered nasal drops containing rhinovirus to 164 healthy adults and found that those with shorter sleep duration were more vulnerable to viral infection than those who slept for over 7 h.11 Lin et al.12 illustrated that patients with insufficient sleep had a longer duration of virus shedding than those who slept over 6 h. A 72-h sleep deprivation experiment showed that natural killer cells continuously declined with prolonged sleep deprivation.13 Bollinger et al.14 investigated serum T cell levels of seven healthy young men during normal sleep and sleep deprivation, and observed that sleep deprivation significantly inhibited CD4(+) and CD25(-) T cell proliferation. In addition, persistent sleep deprivation could promote the accumulation of pro-inflammatory cytokines and chemokines15 and manifest as elevated C-reactive protein (CRP) and interleukin-6 (IL-6) levels,16 which were also the hallmarks of severe COVID-19. Overall, the compromised innate and adaptive immune functions combined with a persistent inflammatory state may explain the higher risk of susceptibility, severity, and longer recovery time observed in patients with sleep disturbances. Fortunately, early intervention for sleep disturbances could attenuate the adverse effects of COVID-19. Clinical evidence has shown that patients with melatonin administration, a drug for improving sleep efficiency, significantly reduced the severity and shortened recovery time of COVID-19.17 Genzor et al.<sup>18</sup> recruited 273 patients with OSA and found that patients with sufficient continuous positive airway pressure adherence, defined as more than 4 h per night over the past ten years, experienced a less severe course of COVID-19 compared with non-users, although the adherent group had more severe OSA at the baseline. The above studies highlighted the importance of early screening and targeted interventions for sleep disturbances.

The effect of pre-existing sleep disturbances on COVID-19 varies at different ages. We found that young

individuals with pre-existing sleep disturbances had a higher susceptibility and hospitalization for COVID-19 than those without. This finding further confirmed the compromised immune function induced by sleep disturbances. Hence, early detection of sleep disturbances was crucial in young populations. In old individuals, those with pre-existing sleep disturbances elevated the hospitalization and mortality of COVID-19 but did not increase the susceptibility compared with those without. Zheng et al.<sup>19</sup> compared the distribution of immune cell types between old and young in healthy groups and patients with COVID-19. They found that in healthy groups, aging promoted the transition of T cells from naïve and memory to extreme effector phenotypes such as effector, exhausted, cytotoxic, and regulatory cell subsets and increased inflammatory monocytes. In addition, old individuals are usually associated with various pre-existing comorbidities such as chronic obstructive pulmonary disease, diabetes, cardiovascular disease, and so on. These comorbidities make them predisposed to COVID-19. Therefore, the effect of age on susceptibility might be counteracted by other risk factors. Considering the poor prognosis in old patients with sleep disturbances, intervention should be initiated as soon as possible.

It is interesting that the effect of sleep disturbances on COVID-19 was different between males and females. Male patients with sleep disturbances had higher mortality of COVID-19. It could be explained from two aspects. Regarding the host factors, the humoral and cellular immune responses of females to the viral infection were stronger than those of males due to inherent immune response.<sup>20</sup> In a murine model of the 2009 H1N1 influenza virus infection, female mice showed higher serum IgG antibody titers and IgA antibody titers of bronchoalveolar lavage fluid and elicited more potent CD4+ T and CD8+ T cell activity compared with male mice.<sup>21</sup> Besides, sex-specific expression of angiotensin-converting enzyme 2 (ACE-2), a receptor for SARS-CoV-2, may explain the increased severity reported in male patients with COVID-19. Viveiros et al.<sup>22</sup> explored the expression and activity of ACE-2 in different organs in both mice and humans. They observed that ACE-2 was higher in the kidneys, hearts, and lungs of males than that of females in different age groups. Data from the protein atlas database also demonstrated that both ACE-2 RNA and protein were highly expressed in the human testes.<sup>23</sup> All these results showed that ACE-2 expressed higher in males than females. In terms of environmental factors, males are more likely to have unhealthy lifestyles and comorbidities (smoking, cardiovascular disease, etc.), which predispose them to adverse COVID-19 outcomes.

Of note, our subgroup analysis showed that only OSA played an essential role in the whole clinical course of COVID-19. Previous meta-analyses demonstrated that OSA was linked to poor outcomes in patients with COVID-19 (intensive care unit admission, severity, mechanical ventilation and mortality),4,5 which was consistent with our results. We further elaborated that the susceptibility to COVID-19 was increased in patients with OSA. However, its mechanism was unclear. A Mendelian randomization study showed no casual association between OSA and COVID-19, which meant that other factors instead of genetic influenced the susceptibility.24 The main pathophysiological features of OSA were sleep fragmentation and nocturnal chronic intermittent hypoxia. As mentioned before, insufficient sleep duration induced by sleep fragmentation was associated with impaired immune function and promoted inflammatory response. In addition, chronic intermittent hypoxia was also a significant risk factor for COVID-19. Cubillos-Zapata et al.<sup>25</sup> reported that chronic intermittent hypoxia could reduce the CD8+ T-cell activation and cytotoxicity by upregulating the programmed death cell receptor and its ligand crosstalk. An in vivo mouse model showed that both intermittent hypoxia and sleep fragmentation reduced intra-tumoral CD8+ Tcell cytotoxicity.26 The above pathophysiology of OSA may be responsible for the increased susceptibility to COVID-19.

At least 10% of patients with COVID-19 experienced persistent symptoms after infection.<sup>1</sup> Long COVID could involve multisystem and last for more than three years, imposing a huge threat to global health. To date, the mechanism of long COVID is unclear, and no intervention is proved to be effective in the prophylactic or therapeutic field. We found that patients with OSA were vulnerable to long COVID. Cortellini et al.<sup>27</sup> recruited 1339 survivors of COVID-19 to investigate the association between inflammatory biomarkers collected at diagnosis and long COVID. They suggested that elevated CRP levels and neutrophil-to-lymphocyte ratios were the predictors of long COVID. Schultheiß et al.<sup>28</sup> included 318 participants and found that high

levels of IL-6, IL-1β, and tumor necrosis factor (TNF) increased the risk of long COVID, and this finding was verified in a validation cohort of 333 participants. It indicated that long COVID was linked to proinflammatory status. Coincidentally, OSA is a chronic low-grade inflammatory disease. A meta-analysis enrolled 51 studies and found that patients with OSA had higher serum levels of CRP, TNF-α, IL-6 and IL-8 than those without.29 Chronic intermittent hypoxia could activate immune cellular pathways, such as nuclear factor-kappa B and toll-like receptor-4 to increase TNF-α, IL-6, and many other inflammatory mediators.<sup>30</sup> Therefore, we supposed that long COVID in patients with pre-existing OSA was caused by chronic inflammation. It is elusive whether continuous positive airway pressure could protect patients with OSA from long COVID, and future studies are needed.

To our knowledge, this is the first meta-analysis focusing on all sleep disturbances, rather than OSA alone, to illustrate the influence of pre-existing sleep disturbances on the entire clinical course of COVID-19. It emphasized that sleep disturbances, especially OSA significantly influenced COVID-19. These influences could be affected by age and gender. This study had some limitations. First, high heterogeneity was observed in all outcomes. We used random-effect models to alleviate the influence of high heterogeneity on the results. Second, owing to the outbreak of COVID-19, all included studies were observational. Thus, no causal relationships could be confirmed. We have performed three subgroup analyses representing good quality, and the results showed that the associations between preexisting sleep disturbances and the four outcomes were consistent with the main analyses. Future randomized controlled trials are expected to investigate the prophylactic and therapeutic effects of timely sleep interventions on the susceptibility and severity of COVID-19.

In conclusion, sleep disturbances, especially OSA, significantly increased the risk of COVID-19 susceptibility, hospitalization, mortality and long COVID. These influences could be affected by age and gender. Early evaluation and prompt intervention for sleep disturbances are necessary to alleviate the short-term and long-term effects of COVID-19.

#### Contributors

Jiawei Zhou developed the concept, designed the study, conducted statistical analysis, interpreted data, and drafted the article. Xia Li, Ting Zhang, Ziyan Liu, and Peng Li provided the study selection, data extraction, and quality assessment. All authors had full access to all the data, and authors (Jiawei Zhou, Xia Li, Ting Zhang, Ziyan Liu, and Peng Li) have verified the underlying data. Na Yu and Wei Wang made equal contributions to manuscript revision and supervision and had final responsibility for the final decision. All authors helped to interpret data and revise the draft of the article. All authors read and approved the final article.

#### Data sharing statement

Data are available on reasonable request. All data relevant to the study are included in the article or uploaded as Supplementary Information.

# Declaration of interests

None.

#### Acknowledgements

The study was supported by a grant from the National Natural Science Foundation of China (project number 82270107) and the Key Laboratory of Respiratory Diseases of Liaoning Province (project number 3110210212).

#### Appendix A. Supplementary data

Supplementary data related to this article can be found at https://doi.org/10.1016/j.eclinm.2024.102719.

#### References

- Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. *Nat Rev Microbiol.* 2023;21(3):133–146.
- 2 Jahrami HA, Alhaj OA, Humood AM, et al. Sleep disturbances during the COVID-19 pandemic: a systematic review, metaanalysis, and meta-regression. *Sleep Med Rev.* 2022;62:101591.
- 3 Besedovsky L, Lange T, Haack M. The sleep-immune crosstalk in health and disease. *Physiol Rev.* 2019;99(3):1325–1380.
- 4 Hariyanto TI, Kurniawan A. Obstructive sleep apnea (OSA) and outcomes from coronavirus disease 2019 (COVID-19) pneumonia: a systematic review and meta-analysis. *Sleep Med.* 2021;82:47–53.
- 5 Hu M, Han X, Ren J, Wang Y, Yang H. Significant association of obstructive sleep apnoea with increased risk for fatal COVID-19: a quantitative meta-analysis based on adjusted effect estimates. *Sleep Med Rev.* 2022;63:101624.
- 6 L Mandel H, Colleen G, Abedian S, et al. Risk of post-acute sequelae of SARS-CoV-2 infection associated with pre-coronavirus disease obstructive sleep apnea diagnoses: an electronic health record-based analysis from the RECOVER initiative. *Sleep*. 2023;46(9):zsad126.
- 7 Chen SJ, Morin CM, Ivers H, et al. The association of insomnia with long COVID: an international collaborative study (ICOSS-II). *Sleep Med.* 2023;112:216–222.
- 8 Pływaczewska-Jakubowska M, Chudzik M, Babicki M, Kapusta J, Jankowski P. Lifestyle, course of COVID-19, and risk of Long-COVID in non-hospitalized patients. *Front Med.* 2022;9: 1036556.
- 9 The World Bank. World bank country and lending groups. https:// datahelpdesk.worldbank.org/knowledgebase/articles/906519-worldbank-country-and-lending-groups. Accessed December 4, 2023.
- 10 Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. *Biometrics*. 2000;56(2):455–463.
- 11 Prather AA, Janicki-Deverts D, Hall MH, Cohen S. Behaviorally assessed sleep and susceptibility to the common cold. *Sleep.* 2015;38(9):1353–1359.
- 12 Lin YN, Zhou LN, Liu ZR, et al. Short sleep duration is associated with prolonged virus shedding in SARS-CoV-2 omicron-infected patients. *Nat Sci Sleep*. 2023;15:547–554.

- 13 De Lorenzo BH, de Oliveira Marchioro L, Greco CR, Suchecki D. Sleep-deprivation reduces NK cell number and function mediated by β-adrenergic signalling. *Psychoneuroendocrinology*. 2015;57:134– 143.
- 14 Bollinger T, Bollinger A, Skrum L, Dimitrov S, Lange T, Solbach W. Sleep-dependent activity of T cells and regulatory T cells. *Clin Exp Immunol.* 2009;155(2):231–238.
- 15 Sang D, Lin K, Yang Y, et al. Prolonged sleep deprivation induces a cytokine-storm-like syndrome in mammals. *Cell.* 2023;186(25): 5500–5516.e21.
- 16 Irwin MR, Olmstead R, Carroll JE. Sleep disturbance, sleep duration, and inflammation: a systematic review and meta-analysis of cohort studies and experimental sleep deprivation. *Biol Psychiatry*. 2016;80(1):40–52.
- 17 Mohamed Taha A, Adel Abdelkader Saed S, Hossam-Eldin Moawad M, et al. Safety and efficacy of melatonin as an adjuvant therapy in COVID-19 patients: systematic review and meta-analysis. *Adv Med Sci.* 2023;68(2):341–352.
- 18 Genzor S, Prasko J, Mizera J, et al. Risk of severe COVID-19 in non-adherent OSA patients. *Patient Prefer Adherence*. 2022;16:3069– 3079.
- 19 Zheng Y, Liu X, Le W, et al. A human circulating immune cell landscape in aging and COVID-19. *Protein Cell*. 2020;11(10):740– 770.
- 20 Ghosh S, Klein RS. Sex drives dimorphic immune responses to viral infections. J Immunol. 2017;198(5):1782–1790.
- 21 Fink AL, Engle K, Ursin RL, Tang WY, Klein SL. Biological sex affects vaccine efficacy and protection against influenza in mice. *Proc Natl Acad Sci U S A.* 2018;115(49):12477–12482.
- 22 Viveiros A, Gheblawi M, Aujla PK, et al. Sex- and age-specific regulation of ACE2: insights into severe COVID-19 susceptibility. J Mol Cell Cardiol. 2022;164:13–16.
- 23 Papadopoulos V, Li L, Samplaski M. Why does COVID-19 kill more elderly men than women? Is there a role for testosterone? *Androl*ogy. 2021;9(1):65–72.
- 24 Gao X, Wei T, Wang H, et al. Causal associations between obstructive sleep apnea and COVID-19: a bidirectional Mendelian randomization study. *Sleep Med.* 2023;101:28–35.
- 25 Cubillos-Zapata C, Balbás-García C, Avendaño-Ortiz J, et al. Agedependent hypoxia-induced PD-L1 upregulation in patients with obstructive sleep apnoea. *Respirology*. 2019;24(7):684–692.
- 26 Akbarpour M, Khalyfa A, Qiao Z, et al. Altered CD8+ T-cell lymphocyte function and TC1 cell stemness contribute to enhanced malignant tumor properties in murine models of sleep apnea. *Sleep.* 2017;40(2).
- 27 Cortellini A, Gennari A, Pommeret F, et al. COVID-19 sequelae and the host proinflammatory response: an analysis from the OnCovid registry. J Natl Cancer Inst. 2022;114(7):979–987.
- 28 Schultheiß C, Willscher E, Paschold L, et al. The IL-1β, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19. *Cell Rep Med.* 2022;3(6):100663.
- 29 Nadeem R, Molnar J, Madbouly ÉM, et al. Serum inflammatory markers in obstructive sleep apnea: a meta-analysis. J Clin Sleep Med. 2013;9(10):1003–1012.
- 30 Kheirandish-Gozal L, Gozal D. Obstructive sleep apnea and inflammation: proof of concept based on two illustrative cytokines. *Int J Mol Sci.* 2019;20(3):459.